NCT06079736Phase 2Terminated

A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

Study sponsor: PepGen Inc · PEPG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-08-28Actual
Enrollment · participants7Actual
Source updated2025-12-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview